RevoMic has secured confirmed government grants for FY2025 and is promoting the development of foundational technology for drug discovery research utilizing quantum and AI technologies. Grant income is scheduled to be recognized as non-operating income within FY2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"RevoMic","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4591-20260723-01.pdf","jir_short_summary":"RevoMic has secured confirmed government grants for FY2025 and is promoting the development of foundational technology for drug discovery research utilizing quantum and AI technologies. Grant income is scheduled to be recognized as non-operating income within FY2026.","jir_summary":"### Performance Overview\nRevoMic received 23.9 million yen (including tax) in FY2025 from a government grant related to the NEDO's cyber-physical development project utilizing quantum and classical hybrid technology, with the total support amount reaching 58.5 million yen (including tax). This support facilitates the development of foundational technology for drug discovery research leveraging quantum and AI technologies, including patent applications and academic paper preparations. In the fiscal midterm ending in March 2027, grant income is scheduled to be recognized as non-operating income, and this has been incorporated into the full-year earnings forecast announced in May 2026.\n\n### Future Outlook and Corporate Activities\nGoing forward, it is expected that the grant income will be recorded as non-operating income in the FY2027 midterm, with continued strengthening of research and development in quantum and AI technologies. The insights gained are highly compatible with aptamer-based drug discovery research and are expected to contribute to more advanced R&D. Financially, the confirmed grants and increasing cumulative support amount are strengthening the foundation for ongoing research activities.","jir_financial_highlights":"Grant Amount: 23.9 million yen (including tax) (Unknown)\nCumulative Grant Amount: 58.5 million yen (including tax) (Unknown)\nFY2027 Midterm Non-Operating Income: Unknown (Scheduled)","jir_category":"","jir_hashtags":"#RevoMic, #IRCategoryRelated, #JapaneseStocks","jir_key_figures":"Confirmed grant amount: 23.9 million yen (including tax)\nCumulative grant amount: 58.5 million yen (including tax)\nFY2027 Midterm Non-Operating Income: Unknown","jir_meta_title":"\u3010RevoMic\u3011Confirmed Grants for Quantum and AI Drug Discovery\uff5cJuly 2026","jir_meta_description":"RevoMic announces confirmed FY2025 grants and progress in research. Expecting to recognize non-operating income within FY2026. Detailed IR information.","jir_og_title":"\u3010RevoMic\u3011Confirmed Grants for Quantum & AI Drug Discovery\uff5cJuly 2026","jir_og_description":"RevoMic announces confirmed FY2025 grants and advancements in research activities. Detailed outlook and latest IR information.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-87014","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n